'Reverse payment' challenge to Pfizer-Ranbaxy Lipitor accord faces some doubts
A federal judge has expressed doubts about finding an antitrust violation in a patent settlement between Pfizer and Ranbaxy that had no major cash transfer, saying that the deal might not...To view the full article, register now.
Already a subscriber? Click here to view full article